$0.09—Stale · unknown old
XETRA • Last print unknown ago
$0.09—Stale · unknown old
Clovis Oncology, Inc. is a biotechnology firm focused on developing innovative cancer therapies, particularly in the field of precision medicine. The company's lead product, Rubraca, is a PARP inhibitor used for the treatment of ovarian cancer, which positions it uniquely in the oncology market, especially in the U.S. and European markets.
Clovis generates revenue primarily through the sale of its oncology drug Rubraca, leveraging its FDA approval and market presence to capture a share of the growing oncology market. The company benefits from high gross margins due to the premium pricing of its specialized cancer therapies, although it faces challenges with operating expenses and negative cash flow.
FDA approval of new indications for Rubraca
Clinical trial results impacting market perception of Rubraca
Partnerships or collaborations with larger pharmaceutical companies
Market share changes in the oncology segment
Regulatory changes impacting drug approval processes
Technological disruption in cancer treatment methodologies
Emergence of new oncology therapies from competitors
Pricing pressures from generic alternatives
Negative operating cash flow affecting liquidity
High dependency on a single product (Rubraca) for revenue
moderate - As a biotech firm, Clovis's performance is somewhat insulated from economic cycles, but healthcare spending patterns can be influenced by broader economic conditions.
Interest rates affect Clovis primarily through the cost of capital for R&D financing. Higher rates could increase borrowing costs and impact investment in new drug development.
minimal - Clovis has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space may find Clovis appealing.
high - The stock has demonstrated significant volatility, with a 1-year return of -94.9%, indicating high risk.